Skip to content
Clinical Trials – home

Axon Clinical s.r.o.

Verified siteinfo

Czechia Ostrovskeho 253/3, Smichov, 150 00 Prague, Czechia

  • 15 trials recruiting
  • Dry age-related macular degeneration · Crohn's disease · Diabetic retinal oedema
  • Adults and children

About Specializations

Axon Clinical s.r.o. in Prague, Czechia specialises in clinical trials of conditions such as Dry age-related macular degeneration, Crohn's disease, Diabetic retinal oedema, Migraine, and other specialisations. This site conducts important research.

Main research areas of the site

Ophthalmology

The medical center is at the forefront of ophthalmology research, focusing on innovative treatments for various eye conditions. The center's work in this field is driven by a commitment to improving visual outcomes and quality of life for patients.

  • Diabetic Macular Edema
  • Age-related Macular Degeneration
  • Geographic Atrophy

Through cutting-edge clinical trials, the center is exploring new therapeutic options, such as intravitreal injections and eye drops, to address these challenging conditions.

Neurology

Specializing in neurology, the medical center is dedicated to advancing the understanding and treatment of neurological disorders. The research conducted here aims to enhance patient care and develop novel therapeutic strategies.

  • Parkinson's Disease
  • Migraine

By investigating the efficacy and safety of new medications and treatment modalities, the center is contributing to significant advancements in managing these complex neurological conditions.

Gastroenterology

The center's gastroenterology research is focused on improving outcomes for patients with inflammatory bowel diseases. The team is committed to discovering effective treatments that can lead to remission and better quality of life.

  • Crohn's Disease
  • Ulcerative Colitis

Through rigorous clinical trials, the center is evaluating new oral medications and biologics, aiming to provide relief and long-term management solutions for these chronic conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ostrovskeho 253/3, Smichov150 00 PragueCzechia
Recruiting now
15 trials
Conditions studied
14
Partner status
Verified site

More sites in PragueCzechia

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

48 clinical trials

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:MORF-057
  • Sponsor:Morphic Therapeutic Inc.

Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Amgen Inc.

A Phase 2/3 Study of intravitreal mk-8748 versus aflibercept in adults with neovascular age‑related macular degeneration

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

A study to compare the efficacy and safety of AVT29 and aflibercept in patients with diabetic macular edema

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Alvotech Swiss AG

Study of Surabgene Lomparvovec Compared to Ranibizumab for Adults with Wet Age-Related Macular Degeneration

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Crohn's disease

Recruiting

Study of icotrokinra for adults with moderately to severely active Crohn's disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Xelafaslatide
  • Sponsor:ONL Therapeutics Inc.

Study of oral BI 1815368 compared to placebo in patients with diabetic macular edema over 48 weeks of treatment

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Boehringer Ingelheim International GmbH

Colitis ulcerative+1

Recruiting

Study on Long-term Safety of Zasocitinib for Adults with Moderate to Severe Ulcerative Colitis and Crohn's Disease

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.